ALNOV:EPA
Novacyt SA
€0.50
arrow_upward
+1.22%(+0.0060) 1 天
9月23日, GMT+2 17:35:22 · EUR
search
所有股票代码
1 天
5 天
1 个月
6 个月
年初至今
1 年
5 年
最大
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 ALNOV 生成关键数据洞见…
开盘价
€0.49
最高价
€0.51
最低价
€0.49
市值
3558.83万
平均成交量
34.15万
成交量
11.78万
52 周最高价
€1.04
52 周最低价
€0.29
每股收益
-€0.39
流通股数
7258.81万
员工人数
216
开盘价
€0.49
最高价
€0.51
最低价
€0.49
市值
3558.83万
平均成交量
34.15万
成交量
11.78万
52 周最高价
€1.04
52 周最低价
€0.29
每股收益
-€0.39
流通股数
7258.81万
员工人数
216
新闻报道
来自网络来源和新闻合作伙伴
资料
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Novacyt SA简介